Supplementary Material

# Supplementary Tables

Supplementary table 1. Literature review characteristics.

|  |  |
| --- | --- |
| Database | Pubmed/Medline |
| Search Period | 01/01/2015- 31/12/2017 |
| Search Strategy | ("lung neoplasms"[MeSH Terms] AND (randomized controlled trial[All Fields] OR randomized controlled trials[All Fields] OR randomized controlled trial[All Fields] OR randomised controlled trials[All Fields] OR randomized controlled trial[Publication Type] OR Review[ptyp] OR systematic[sb]) AND ("Quality of Life"[Mesh] OR "Quality Indicators, Health Care"[Mesh] OR "Patient Outcome Assessment"[Mesh] OR patient reported outcome\*[tiab] OR patient related outcome\*[tiab] OR patient-reported outcome\*[tiab] OR patient-related outcome\*[tiab] OR patient reported outcome\*[ot] OR patient related outcome\*[ot] OR patient-reported outcome\*[ot] OR patient-related outcome\*[ot] OR "Treatment Outcome"[Mesh]) |
| Filters | English [Lang]; Clinical Trials |

Supplementary table 2. Case mix variables proposed during the scientific committee and nominal group meetings.

Legend:

ALK: Anaplastic lymphoma kinase; BMI: body mass index; BRAF: v-raf murine sarcoma viral oncogene homolog B1; EGFR: Epidermal Growth Factor Receptor; FEV-1: forced expiratory volume; CV: Cardiovascular; PD-L1: Programmed Death-ligand 1; ROS-1: Reactive Oxygen Species.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Scientific Committee meeting** | **Nominal group 1** | **Nominal group 2** | **Nominal group 3** | **Nominal group 4** |
| **Demographic factors** | | | | |
| * Age * Gender * Ethnicity * Educational level | * Age * Gender * Ethnicity * Height and weight * Family status * Occupational exposure | * Age * Gender * Ethnicity * Family support * Employment status | * Age * Gender * Ethnicity * Educational level * Occupational exposure | * Age * Gender * BMI * Occupational exposure to asbestos * Employment status * Socio-economic status * Presence of a caregiver |
| **Baseline clinical factors** | | | | |
| * Unintentional weight loss * Smoking status (pack-year index) * Pulmonary function (FEV1) * Comorbidities (Modified Self-administered Comorbidity Questionnaire) | * Unintentional weight loss * Smoking status (pack-year index) * Pulmonary function (FEV1) * Comorbidities (according to clinical record: CV disease, pulmonary, renal or liver disease, endocrine disorders, immunological disease, recent surgery) | * Unintentional weight loss * Smoking status * Pulmonary function (FEV1)   Comorbidities (according to clinical record: CV disease, pulmonary, renal or liver disease, auto-immune disease, diabetes, recent surgery, hearing impairment). | * Unintentional weight loss * Smoking status (pack-year index) * Comorbidities (Modified Self-administered Comorbidity Questionnaire) * Health-related quality of life (any validated instrument) | * Unintentional weight loss * Smoking status (pack-year index + classification as smoker, non-smoker, ex-smoker) * Comorbidities |
| Baseline tumor factors | | | | |
| * Clinical stage (TNM) * Pathological stage (TNM) * Histology * EGFR mutation * ALK translocation * ROS-1 rearrangement * PD-L1 expression | * Clinical stage (TNM) * Pathological stage (TNM) * Histology * EGFR mutation * ALK translocation * ROS-1 rearrangement * PD-L1 expression | * Clinical stage (TNM) * Pathological stage (TNM) * Histology * EGFR mutation * ALK translocation * ROS-1 rearrangement * PD-L1 expression * BRAF * % of diagnosis based on biopsy/cytology | * Clinical stage (TNM) * Pathological stage (TNM) * Histology * EGFR mutation * ALK translocation * ROS-1 rearrangement * PD-L1 expression | * Clinical stage (TNM) * Pathological stage (TNM) * Histology * EGFR mutation * ALK translocation * ROS-1 rearrangement * PD-L1 expression * BRAF * Number of metastases * Brain metastases |
| **Treatment Factors** | | | | |
| * Treatment intent (curative/palliative) * Completed treatment (w/o dose reduction) | * Treatment intent (curative/palliative) * Completed treatment (w/o dose reduction) * Allergies * Treatment withdrawal (with reasons) | * Treatment intent (curative/palliative) * Completed treatment * Treatment withdrawal * Dose reduction | * Treatment intent (curative/palliative) | * Treatment intent (curative/palliative) * Completed treatment (w/o dose reduction) * First line of treatment * Administration route (oral, intravenous, subcutaneous) * Local treatment received (type) |

Supplementary table 3. Outcomes variables proposed during the scientific committee and nominal group meetings.

Legend:

CTCAE: Common Terminology Criteria for Adverse events; ECOG: Eastern Cooperative Oncology Group; EORTC: European Organisation for Research and Treatment of Cancer; EQ-5D: EuroQol; ER: emergency room; HRQoL: Health related quality of life; LCSS: Lung Cancer Symptoms Scale; PRO-CTCAE: Patient-Reported Outcomes version of the CTCAE; QLQ- LC13:Lung Cancer-specific quality of life questionnaire; SERMAS: Servicio Madrileño de Salud

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Scientific Committee meeting** | **Nominal group 1** | **Nominal group 2** | **Nominal group 3** | **Nominal group 4** |
| **Degree of health** | | | | |
| * Performance status (ECOG) * Patient-reported health status: Global health status, physical and emotional function; fatigue, vitality, pain, cough, difficulty breathing, hemoptysis, loss of appetite, insomnia, constipation, diarrhea, weight loss (measured with a specific and a general HRQoL questionnaire) | * Performance status (ECOG) * Patient-reported health status: Global health status, physical and emotional function; fatigue, vitality, pain, cough, difficulty breathing, hemoptysis, loss of appetite, (measured with LCSS + EQ-5D) | * Performance status (ECOG) * Patient-reported health status: Global health status, physical and emotional function; fatigue, vitality, pain, cough, difficulty breathing, hemoptysis, loss of appetite, (measured with LCSS + EQ-5D) or Global health status, physical and emotional function; pain, cough, difficulty breathing, hemoptysis, weight loss, (measured with EORT-QLQ-LC-13 + EQ-5D) | * Performance status (ECOG) | * Performance status (ECOG) * Patient-reported health status: Global health status, physical and emotional function; fatigue, vitality, pain, cough, difficulty breathing, hemoptysis, loss of appetite, (measured with LCSS + EQ-5D) |
| **Survival** | | | | |
| * Overall survival * Cause of death | * Overall survival * Cause of death * Number of treatment lines * Progression-free survival * Progression-free survival (1st treatment line) | * Overall survival * Cause of death | * Overall survival * Cause of death * Number of treatment lines * Progression-free survival (clinical evaluation and/or radiographic progression) | * Overall survival * Cause of death * Progression-free survival * Clinical benefit (time) * Time to treatment failure * Time to next treatment |
| **Quality of death** | | | | |
| * Place of death * Length of hospital stay during end of life period * Aggressive intervention and palliative care (Earle criteria) * Existence or doctor´s knowledge about the living will of patients | * Place of death * Length of hospital stay during end of life period * Aggressive intervention and palliative care (Earle criteria 1, 2, 5 and 6) * Doctor´s knowledge about the living will of patients * Access to palliative care (y/n) | * Place of death * Aggressive intervention and palliative care (Earle criteria 1-3) * Existence or doctor´s knowledge about the living will of patients | * Place of death * Therapeutic aggressiveness in the end of life (antineoplastic treatment in the last 14 days) and access to palliative care (at least 3 months before death). * Existence or doctor´s knowledge about the living will of patients | * Place of death * Length of hospital stay during end of life period * Administration of active treatment in the last month (y/n) * Change of treatment in the last month (y/n) * ICU admission in the last month (y/n) * ER admission in the last month * Access to palliative care in the last month |
| **Acute complications of treatment** | | | | |
| * Major surgical complications (Indicators of the SERMAS observatory) * Major systemic therapy or/and radiotherapy complications (CTCAE and PRO-CTCAE) | * Major surgical complications (surgical complications and post-operative mortality) * Major systemic therapy or/and radiotherapy complications (CTCAE and PRO-CTCAE) | * Major surgical complications (surgical complications and post-operative mortality) * Major systemic therapy or/and radiotherapy complications (CTCAE and PRO-CTCAE) | * Major surgical complications (Indicators of the SERMAS observatory) * Major systemic therapy or/and radiotherapy complications (CTCAE and PRO-CTCAE) | * Major surgical complications (surgical complications, re-admission due to surgical complications and post-operative mortality) * Major systemic therapy or/and radiotherapy complications (list of the 5 most relevant complications according to treatment type) * Treatment withdrawal due to toxicity * Patient wish to withdraw the treatment due to toxicity |
| **Others** | | | | |
| * Date of diagnosis * Productivity loss of the patient and caregiver (sick leave) * resource use (ER admission, unscheduled specialist visits, hospitalizations) | * Date of diagnosis * Productivity loss of the patient and caregiver (sick leave) * resource use (ER admission, unscheduled specialist visits, hospitalizations) * Treatment start date * Patients’ preferences | * Date of diagnosis * Productivity loss of the patient and caregiver (sick leave) * resource use (ER admission, unscheduled specialist visits, hospitalizations, nurse visit) * Treatment start date | * Date of diagnosis * Independence in activities   of daily living | * Date of diagnosis * Adherence to treatment * Time to diagnosis * Time to first treatment |